Biogen Idec Inc (BIIB) 341.73 $BIIB
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Marketwire - 13 mins ago
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.59%
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 1.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Chipotle, Facebook Rally On Upside Earnings Surprise
at Investor's Business Daily - Fri Jul 25, 5:36PM CDT
Several leading stocks enjoyed solid, earnings-powered breakouts last week. The IBD 50 outperformed the overall market with a 3.2% gain, thanks to some outsized performances by some big names. Chipotle Mexican Grill (CMG) gapped up and soared 12%...
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.
AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 10:52AM CDT
AbbVie (ABBV) will provide additional details on the upcoming Shire acquisition this fall.
Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 8:39AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as its shares rose over 11% on the day.
Celsion (CLSN) in Focus: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:51AM CDT
Celsion Corp. (CLSN) was a big mover last session, as its shares rose over 5% on the day.
Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:44AM CDT
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares shoot up over 11% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:40PM CDT
UCB SA (UCBJF) announced positive top-line results from a phase III study on epilepsy candidate, brivaracetam.
Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...
Royal Caribbean and Facebook are big market movers
AP - Thu Jul 24, 3:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
Actelion Beats on Q2 Earnings and Sales, Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:50PM CDT
Actelion LTD. (ALIOF) reported second-quarter earnings of $2.83 per American Depository Receipt (ADR), up 203.77% from the prior-year earnings of 93 cents per ADR, beating the Zacks Consensus Estimate of $1.37 per share.
Why Biogen Idec Stock Is Firing on All Cylinders
Cory Renauer, The Motley Fool - Motley Fool - Thu Jul 24, 1:00PM CDT
Biogen Idec 's latest earnings report is the envy of the industry as Tecfidera keeps marching toward its multi-billion dollar potential. Beyond multiple sclerosis collaboration revenue from Roche 's best-selling cancer therapy Rituxan continues to...
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Marketwire - 13 mins ago
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.59%
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 1.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Chipotle, Facebook Rally On Upside Earnings Surprise
at Investor's Business Daily - Fri Jul 25, 5:36PM CDT
Several leading stocks enjoyed solid, earnings-powered breakouts last week. The IBD 50 outperformed the overall market with a 3.2% gain, thanks to some outsized performances by some big names. Chipotle Mexican Grill (CMG) gapped up and soared 12%...
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.
AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 10:52AM CDT
AbbVie (ABBV) will provide additional details on the upcoming Shire acquisition this fall.
Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 8:39AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as its shares rose over 11% on the day.
Celsion (CLSN) in Focus: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:51AM CDT
Celsion Corp. (CLSN) was a big mover last session, as its shares rose over 5% on the day.
Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:44AM CDT
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares shoot up over 11% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:40PM CDT
UCB SA (UCBJF) announced positive top-line results from a phase III study on epilepsy candidate, brivaracetam.
Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...
Royal Caribbean and Facebook are big market movers
AP - Thu Jul 24, 3:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
Actelion Beats on Q2 Earnings and Sales, Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:50PM CDT
Actelion LTD. (ALIOF) reported second-quarter earnings of $2.83 per American Depository Receipt (ADR), up 203.77% from the prior-year earnings of 93 cents per ADR, beating the Zacks Consensus Estimate of $1.37 per share.
Why Biogen Idec Stock Is Firing on All Cylinders
Cory Renauer, The Motley Fool - Motley Fool - Thu Jul 24, 1:00PM CDT
Biogen Idec 's latest earnings report is the envy of the industry as Tecfidera keeps marching toward its multi-billion dollar potential. Beyond multiple sclerosis collaboration revenue from Roche 's best-selling cancer therapy Rituxan continues to...
